CVS's claims against Epic are dismissed without prejudice (leave to amend is standard in this MDL). Monitor whether CVS files an amended complaint re-pleading specific facts about Epic's role in the Ursodiol conspiracy. The broader MDL continues against other manufacturers, so CVS's overall antitrust recovery prospects are not eliminated.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $80.49entry
- T+1 · 9mo ago +0.10%α −0.61% · $80.57
- T+5 · 8mo ago −5.18%α −4.72% · $76.32
- T+20 · 8mo ago −10.77%α −6.36% · $71.82
- T+60 · 6mo ago +15.51%α +4.59% · $92.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
In the Generic Pharmaceuticals MDL, Judge Rufe granted in part and denied in part Epic Pharma's motions to dismiss antitrust claims. CVS's complaint against Epic was dismissed for failure to state a claim, as it lacked specific allegations linking Epic to any conspiracy regarding Ursodiol. This is a procedural win for Epic and removes CVS from this particular litigation track, but the ruling is interlocutory and does not resolve the broader MDL.
Court Ruling Details
Key Facts
- CVS Pharmacy, Inc. v. Actavis Elizabeth, LLC, et al. (2:20-cv-06310) was one of three complaints dismissed against Epic Pharma for failure to state a claim.
- The court found CVS's complaint lacked any specific act by Epic regarding Ursodiol, no meeting, phone call, or price hike was alleged.
- Epic's motions to dismiss were denied as to eight other complaints (including those by Kroger, Humana, Rite Aid, Walgreens, UnitedHealth, and others) which sufficiently alleged a conspiracy.
- The ruling is a motion-to-dismiss decision under Rule 12(b)(6); it does not adjudicate the merits of the broader antitrust conspiracy allegations.
- CVS remains a plaintiff in the MDL against other defendants; only claims against Epic were dismissed.
Financial Impact
No damages awarded or quantified in this ruling. The dismissed complaint sought unspecified treble damages under antitrust law.
Risk Factors
- CVS may need to re-plead with greater specificity to rejoin the case against Epic.
- If CVS does not amend, it loses any potential recovery from Epic in this MDL.
- The ruling is interlocutory and not appealable as of right; no immediate financial impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1as9hv5f-CVS |
Track record
25 reports on CVS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
- Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
- Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
- Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
- Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
- Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers